- KAER's technology allows high doses of drugs to be delivered to the lungs directly instead of intravenously
MOUNTAIN VIEW, California, Feb. 26, 2013 /PRNewswire/ -- Based on its recent analysis of the aerosol drug delivery technology market, Frost & Sullivan recognizes KAER Biotherapeutics with the 2012 North America Frost & Sullivan Award for Technology Innovation for SUPRAER™. KAER has developed and patented the SUPRAER™ technology, which is a new platform for aerosolizing biologics and delivering them to the lungs without the use of any excipients. As this technology completely eliminates the safety issues normally associated with excipients, it saves costs on animal trials.
The SUPRAER™ technology generates a large aqueous aerosol of the biologic, which is then rapidly dried, concentrated, and delivered as a solid-phase respirable aerosol, pure in constituency. The creation of liquid droplets, which shrink to the desired respirable particle size range for deep lung administration when dried, requires less shear-inducing energy than present jet nebulizers.
"The technology consists of a proprietary low-shear spray nozzle, in combination with an innovative particle-drying chamber and a low-resistance particle concentrator," said Frost & Sullivan Research Analyst Darshana De. "The combination helps generate high concentrations of hollow particles in an aerosol-based drug delivery system. These hollow particles can carry a larger mass than solid particles having the same aerodynamic diameter."
The SUPRAER™ technology can deliver drugs directly and effectively to the lungs with an 80 percent reduction in dosage compared to intravenous administration. Consequently, it prevents the occurrence of harmful systemic side effects.
SUPRAER™ also has the ability to deliver respirable aerosols generated from relatively viscous solutions of large molecules. The aerosol generation nozzle aerosolizes solutions of large active molecules, without degrading the biological activity of the aerosol.
This technology should have greater acceptance among patients, as it provides for enhanced therapeutic effects, requires a shorter treatment time, and reduces side effects. For pharmaceutical companies, this is a new delivery option with reduced cost of goods (COGS), as they need to use fewer quantities of biologics for effective therapeutic outcomes.
"Due to the inherent disadvantage of existing aerosol delivery systems, most biologics are administered intravenously," observed Darshana. "KAER Biotherapeutics efficiently addresses this issue with an innovative solution that can directly deliver drugs to the lungs and significantly reduce the total dose, cost of therapy, and systemic toxicities."
Each year, Frost & Sullivan presents this award to the company that has demonstrated technological innovation within its industry. This Award recognizes the ability of the company to successfully develop and introduce new/disruptive technology, formulate a well-designed product family, and make significant technology contributions to the industry.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About KAER Biotherapeutics
Clinical research has indicated that inhalation of biotherapeutics is an effective alternative for the treatment of both respiratory and systemic diseases. Aerosol delivery through the respiratory tract is the preferred mode of administration for lung diseases. The ability to deliver these agents directly to the lungs reduces the total dose of the agent, the cost of therapy, as well as systemic toxicities.
KAER Biotherapeutics Corporation, based out of California, has come up with a novel high-dose drug delivery system that can aerosolize and deliver 100's of milligrams of a biologic-based drug to the lungs quickly. Their patented SUPRAER technology can now deliver aerosol therapy to the lungs in a convenient time frame that other aerosol drug delivery technologies have not been able to achieve. With the SUPRAER technology, a reduction in dose of more than 80% of the drugs can be realized when delivered directly to the lungs compared to intravenous administration, which consequently leads to cost savings and reduction in unwanted side-effects.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
P: +1.210. 247.3870
SOURCE Frost & Sullivan